Despite the approval of PD-1/PD-L1 inhibitors for recurrent/metastatic HNSCC, clinical response rates remain modest (15–20%), attributed to spatial heterogeneity, the absence of tertiary lymphoid structures, CXCL13+CD8+ T cell exhaustion, and tumor mutational burden (39). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.